IP Library › Granted Patent US 10,426,796
Granted Patent B2
US 10,426,796 · App. 15/619,467 · Granted Oct 1, 2019

Compositions for biological systems and methods for preparing and using the same

Inventors: Christopher D. Jones (Eagle, ID); Nathan Quintanar (Boise, ID); Roshan Patel (Daly City, CA)
Assignee: SMART Surgical, Inc.
A61K35/17A61K35/28A61K38/18A61K47/02A61K47/20A61K47/26A61K47/42C12N5/0037A61K2035/124C12N2500/34C12N2500/90
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,426,796
App. No.
15/619,467
Granted
Oct 1, 2019
Kind
B2
Abstract

A composition for influencing biological growth includes a solution having a first volume and having low pH fluid base including dextrose, and albumin, wherein the concentration of albumin in the solution is between about 10 mg/ml and about 150 mg/ml.

Claims (32)

1. A composition for performing a medical therapy, comprising:

a low pH fluid base, wherein the low pH fluid base comprises dextrose;

mononuclear cells obtained from human umbilical cord blood; and

albumin, wherein the concentration of albumin is between about 10 mg/ml and about 150 mg/ml, and wherein the composition is configured for implantation within a human subject.

2. The composition of claim 1 , wherein the pH of the composition is between 5.0 and 7.4.

3. The composition of claim 1 , wherein the pH of the composition is between 4.1 and 7.2.

4. The composition of claim 1 , wherein the pH of the composition is between 4.1 and 6.2.

5. The composition of claim 1 , wherein the pH of the composition is between 5.0 and 6.2.

6. The composition of claim 1 , further comprising sodium bicarbonate.

7. The composition of claim 1 , further comprising calcium bicarbonate.

8. The composition of claim 1 , wherein the albumin is from commercially available human serum.

9. The composition of claim 1 , wherein the albumin is from donor-derived serum.

10. The composition of claim 1 , wherein the albumin is from human umbilical cord blood.

11. The composition of claim 1 , wherein the concentration of albumin is between about 10 mg/ml and about 120 mg/ml.

12. The composition of claim 1 , wherein the concentration of albumin is between about 50 mg/ml and about 150 mg/ml.

13. The composition of claim 1 , wherein the concentration of albumin is between about 105 mg/ml and about 150 mg/ml.

14. The composition of claim 1 , wherein the composition does not contain dimethyl sulfoxide (DMSO).

15. The composition of claim 1 , wherein the low pH fluid base further comprises dextran.

16. The composition of claim 1 , wherein the low pH fluid base further comprises dimethyl sulfoxide (DMSO).

17. The composition of claim 1 , wherein the low pH fluid base further comprises a cryopreservative.

18. The composition of claim 1 , further comprising stem cells.

19. The composition of claim 18 , wherein the stem cells consist of non-expanded cell populations.

20. The composition of claim 18 , wherein the stem cells comprise hematopoietic stem cells (HSC).

21. The composition of claim 18 , wherein the stem cells comprise mesenchymal stem cells (MSC).

22. The composition of claim 1 , wherein the composition comprises between about 100,000 and about 75 million live mononuclear cells per ml.

23. The composition of claim 1 , wherein the composition comprises between about 10 million and about 30 million live mononuclear cells per ml.

24. The composition of claim 1 , wherein the composition comprises between about 2.5 million and about 10.2 million live mononuclear cells per ml.

25. The composition of claim 1 , wherein the mononuclear cells are derived only from umbilical cord blood of a single donor.

26. The composition of claim 1 , further comprising one or more bioactive agents.

27. The composition of claim 26 , wherein the one or more bioactive agents comprise one or more cytokines.

28. The composition of claim 26 , wherein the one or more bioactive agents comprise one or more growth factors.

29. The composition of claim 26 , wherein the one or more bioactive agents are selected from the group consisting of macrophage inflammatory protein alpha (MIP-1α), macrophage inflammatory protein beta (MIP-1β), interferon gamma-induced protein 10 (IP-10), interleukin 1 Beta (IL-1β), interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 5 (IL-5), interleukin 6 (IL-6), interleukin 7 (IL-7), interleukin 8 (IL-8), interleukin 9 (IL-9), interleukin 10 (IL-10), interleukin 12 (IL-12), interleukin 13 (IL-13), interleukin 15 (IL-15), interleukin 17 (IL-17), interleukin 18 (IL-18), interleukin 21 (IL-21), interleukin 22 (IL-22), interleukin 23 (IL-23), interleukin 27 (IL-27), interleukin 31 (IL-31), interferon alpha (INFα), a lymphokine, granulocyte macrophage colony stimulating factor (GM-CSF), stem cell factor (KL), tumor necrosis factor alpha (TNF-α), vascular endothelial growth factor (VEGF), nerve growth factor, platelet-derived growth factor (PDGF), fibroblast growth factor 2 (FGF-2), epidermal growth factor (EGF), keratinocyte growth factor, transforming growth factor (TGF), insulin-like growth factor, des(1-3)-IGF-I (brain IGF-I), neurotrophin-3 (NT-3), brain-derived neurotrophic factor (BDNF), eotaxin, CXC ligand 1 (GROα), interleukin 1 receptor antagonist (IL-1RA), interleukin 1 alpha (IL-1α), leukemia inhibitory factor (LIF), placental growth factor (PLGF), chemokine ligand 5 (RANTES), stem cell factor (SCF), stromal cell derived factor (SDF1α), and tumor necrosis factor (TNF β).

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 10, 2017
From: JONES, CHRISTOPHER D.; QUINTANAR, NATHAN
To: SMART SURGICAL, INC.
Reel/Frame 043265/0037 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 10, 2017
From: PATEL, ROSHAN
To: SMART SURGICAL, INC.
Reel/Frame 043265/0052 →
Continuity (2)
Provisional Application 62349633 · Jun 13, 2016
Related Publication 20170354683A1 · Dec 14, 2017